foxo4 dri senolytic peptide human trial 2024 FOXO4-DRI Dosing Guide: Peptide Protocol (June 2026) The disordered p53 transactivation domain
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment npj Aging FOXO4 DRI FOXO4 p53 Peptide Peptagon FOXO4 D Retro Inverso(DRI) peptide
Pay in 4 interest-free payments of $7.29 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 15 - Sep 20



